PMID- 27079839
OWN - NLM
STAT- MEDLINE
DCOM- 20170118
LR  - 20210208
IS  - 1097-0339 (Electronic)
IS  - 1097-0339 (Linking)
VI  - 44
IP  - 7
DP  - 2016 Jul
TI  - Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive 
      Mesothelial Cells With FISH Analysis of p16.
PG  - 591-8
LID - 10.1002/dc.23490 [doi]
AB  - BACKGROUND: Mesothelioma patients often present with serosal effusions, which are 
      ideal for cytopathological diagnoses. However, the morphological overlap between 
      malignant and benign mesothelial proliferation can make a conclusive cytological 
      diagnosis of mesothelioma elusive because immunohistochemical staining does not 
      discriminate definitively between the two in this setting. p16 is deleted in up 
      to 80% of pleural mesotheliomas. The aim of this study was to establish the 
      correlation between the p16 deletion status of the cell block with that of its 
      corresponding tumor using fluorescence in situ hybridization (FISH) analysis for 
      individual patient tumors. METHODS: Twenty-two biopsies and 24 corresponding cell 
      blocks, containing serosal effusions with atypical mesothelial cells from 22 
      patients with histologically confirmed pleural mesotheliomas, were analyzed with 
      p16 FISH. Seventeen cell blocks consisting of serosal effusions with reactive 
      mesothelial cells from nonmesothelioma cases were also analyzed. Combined 
      immunofluorescence and FISH were also performed. RESULTS: Seventeen of the 22 
      mesothelioma patients (77.3%) showed homozygous deletions of p16 in the tumor 
      tissue and in the atypical mesothelial cells from the cell blocks. p16 FISH 
      followed by immunofluorescence with EMA was helpful towards identifying the 
      mesothelioma cells in the cell blocks. CONCLUSION: We confirmed that the p16 FISH 
      results obtained from the cell blocks are as reliable as those from the tissue 
      sections. Cell block analysis is recommended for patients with serosal effusions 
      of unknown origins with the following methods: immunohistochemistry should be 
      performed to validate the mesothelial origin, and p16 FISH should be performed to 
      confirm malignancy. Diagn. Cytopathol. 2016;44:591-598. (c) 2016 Wiley Periodicals, 
      Inc.
CI  - (c) 2016 Wiley Periodicals, Inc.
FAU - Hiroshima, Kenzo
AU  - Hiroshima K
AD  - Department of Pathology, Tokyo Women's Medical University, Yachiyo Medical 
      Center, Yachiyo, Japan.
FAU - Wu, Di
AU  - Wu D
AD  - Department of Pathology, Tokyo Women's Medical University, Yachiyo Medical 
      Center, Yachiyo, Japan.
FAU - Hasegawa, Mizue
AU  - Hasegawa M
AD  - Department of Respirology, Tokyo Women's Medical University, Yachiyo Medical 
      Center, Yachiyo, Japan.
FAU - Koh, Eitetsu
AU  - Koh E
AD  - Department of Thoracic Surgery, Tokyo Women's Medical University, Yachiyo Medical 
      Center, Yachiyo, Japan.
FAU - Sekine, Yasuo
AU  - Sekine Y
AD  - Department of Thoracic Surgery, Tokyo Women's Medical University, Yachiyo Medical 
      Center, Yachiyo, Japan.
FAU - Ozaki, Daisuke
AU  - Ozaki D
AD  - Department of Pathology, Chiba Rosai Hospital, Ichihara, Japan.
FAU - Yusa, Toshikazu
AU  - Yusa T
AD  - Department of Thoracic Surgery, Chiba Rosai Hospital, Ichihara, Japan.
FAU - Walts, Ann E
AU  - Walts AE
AD  - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los 
      Angeles, California.
FAU - Marchevsky, Alberto M
AU  - Marchevsky AM
AD  - Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los 
      Angeles, California.
FAU - Nabeshima, Kazuki
AU  - Nabeshima K
AD  - Department of Pathology, Fukuoka University Hospital and School of Medicine, 
      Fukuoka, Japan.
FAU - Tada, Yuji
AU  - Tada Y
AD  - Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, 
      Japan.
FAU - Shimada, Hideaki
AU  - Shimada H
AD  - Department of Surgery, School of Medicine, Toho University, Tokyo, Japan.
FAU - Tagawa, Masatoshi
AU  - Tagawa M
AD  - Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, 
      Chiba, Japan.
LA  - eng
PT  - Journal Article
DEP - 20160415
PL  - United States
TA  - Diagn Cytopathol
JT  - Diagnostic cytopathology
JID - 8506895
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CDKN2A protein, human)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Neoplasm Proteins)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Case-Control Studies
MH  - Cyclin-Dependent Kinase Inhibitor p16
MH  - Diagnosis, Differential
MH  - Epithelial Cells/metabolism/pathology
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Mesothelioma/metabolism/*pathology
MH  - Middle Aged
MH  - Neoplasm Proteins/genetics/*metabolism
MH  - Pleural Neoplasms/metabolism/*pathology
OTO - NOTNLM
OT  - cell block
OT  - cytology
OT  - fluorescence in situ hybridization (FISH)
OT  - immunofluorescence
OT  - mesothelioma
OT  - p16
EDAT- 2016/04/16 06:00
MHDA- 2017/01/19 06:00
CRDT- 2016/04/16 06:00
PHST- 2015/10/30 00:00 [received]
PHST- 2016/03/01 00:00 [revised]
PHST- 2016/03/30 00:00 [accepted]
PHST- 2016/04/16 06:00 [entrez]
PHST- 2016/04/16 06:00 [pubmed]
PHST- 2017/01/19 06:00 [medline]
AID - 10.1002/dc.23490 [doi]
PST - ppublish
SO  - Diagn Cytopathol. 2016 Jul;44(7):591-8. doi: 10.1002/dc.23490. Epub 2016 Apr 15.